Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
about
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaHave we made progress in the management of chronic graft-vs-host disease?Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.Clinical and biological predictors of outcome following relapse of CML post-allo-SCTChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryRecommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.EM23, A Natural Sesquiterpene Lactone from Elephantopus mollis, Induces Apoptosis in Human Myeloid Leukemia Cells through Thioredoxin- and Reactive Oxygen Species-Mediated Signaling Pathways.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisHow I treat newly diagnosed chronic phase CMLConditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignanciesPrevalence of hematopoietic cell transplant survivors in the United States.Management of chronic myeloid leukemia in childhood.Metabolic syndrome in patients with hematological diseases.Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Long-term complications after hematopoietic cell transplantation.Chronic myeloid leukemia: past, present, future.Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.Classification systems for chronic graft-versus-host disease.NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationRecommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT.Hematology: curing CML with imatinib--a dream come true?How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?
P2860
Q34022125-A3717351-F935-4954-931C-7A6CB681B6FDQ34522789-4C55E7B6-4894-40E1-9AEB-81223F7863ACQ34644980-74FC244A-E588-4A3D-88DD-DAE3B55F2FF4Q35023409-01379152-BEB2-46AA-B3F8-DD5E2DDD26F1Q35054717-35C584B0-E1FD-4F1B-8565-30970DF72583Q35633858-7EFDC29F-3B72-4ED7-80AF-0A860FBA30E5Q35634865-ACA75B79-29E4-4937-89F5-06FD99B18480Q35757247-A04E7894-773D-4772-8EA0-B53E0659888DQ36219840-9A3D57D4-7E11-43E7-862E-BFE97DE2C46AQ36734783-08C5F2BB-EE69-4CFC-AA9D-AAE4180D5CDAQ36928803-A6065B8E-C902-4CC3-9936-2BEC3A17B7A4Q37027767-3C9485F8-206D-4180-8FDE-4B0578DEF505Q37180878-C2BACB83-6C66-45E8-A7A4-43762FEE97D9Q37188807-96DF7B70-5034-4823-8312-A0AE45FCD411Q37991223-B15D4A06-7A3E-4B8F-8AED-D70E282BB86FQ38044776-E203F659-4A12-4C3F-B4A1-E84746664BDDQ38046648-4DE71120-C260-4345-89EB-99667F337B40Q38216677-1CDC77C9-B4CF-44A5-B9FE-6E574C04B2A8Q38585916-95968AF1-D203-438B-9D71-C8AEB4B09858Q38667959-A72C3CBB-845B-4789-A4DB-4424676448F6Q38694690-2C77F072-F231-4A69-A83F-7487857896BAQ38823260-B92B69DB-E01C-42CB-A32D-FA08EBCA41E1Q38937497-0965A160-671B-42CE-8B71-92629EF9B186Q39002161-E142B7A0-7711-4F0F-B4DF-685C8DE62871Q39140290-DE9112CF-4A6A-4E82-8F1D-D2D7501106EAQ41038941-7A0EA0E3-A63A-44B8-B5AD-C50000A2ECFCQ42111313-AFEC5F90-152A-4F36-8FD4-1E39357B795CQ42230889-DED54839-41C1-424B-A7F3-F93F62A352E8Q43218850-2A90B74E-1771-4A88-96D7-B48C72DA75E5Q46031355-1ED1E5FB-84CD-46BB-92CB-766F57102FD7Q47594277-8FB69508-5802-4E88-BC7A-A111A7A3D88BQ48162932-140A1EE8-9A44-45E8-827E-AF690B2F0516Q49873738-26483F65-7518-4C24-BBB9-5D940FC9E0ADQ52687293-0110D089-2AF2-48BB-BA77-68D03798C3C1Q54289224-819B782B-5392-4FE6-9202-77B550F1177B
P2860
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Relapse and late mortality in ...... ukemia in first chronic phase.
@ast
Relapse and late mortality in ...... ukemia in first chronic phase.
@en
type
label
Relapse and late mortality in ...... ukemia in first chronic phase.
@ast
Relapse and late mortality in ...... ukemia in first chronic phase.
@en
prefLabel
Relapse and late mortality in ...... ukemia in first chronic phase.
@ast
Relapse and late mortality in ...... ukemia in first chronic phase.
@en
P2093
P2860
P356
P1476
Relapse and late mortality in ...... ukemia in first chronic phase.
@en
P2093
J Douglas Rizzo
John M Goldman
John P Klein
Kathleen A Sobocinski
Mary M Horowitz
Mukta Arora
Navneet S Majhail
Zhiwei Wang
P2860
P304
P356
10.1200/JCO.2009.26.7757
P407
P577
2010-03-08T00:00:00Z